News End of the line for Cassava's troubled Alzheimer's programme The saga of Cassava Sciences' development of Alzheimer's disease therapy simufilam has come to its dismal end.
News Phase 3 readout puts Opthea at risk of insolvency After its lead wet AMD drug failed a phase 3 trial, Opthea may have to make massive repayments to investors that would threaten its viability.
News Gantenerumab 'shows sign of preventing Alzheimer's dementia' A study has suggested early targeting of amyloid in the brains of people with inherited Alzheimer's can delay symptoms, but not all are convinced.
News J&J's nipocalimab fast-tracked for Sjogren's disease Johnson & Johnson's FcRn inhibitor nipocalimab has been awarded fast-track status by the FDA as a treatment for Sjogren's disease.
News EnteroBiotix cues up larger trial of microbiome IBS therapy EnteroBiotix has reported phase 2a proof-of-concept data for its therapy for irritable bowel syndrome (IBS) based on gut microbiome species.
News Vertanical's cannabis-based painkiller hits target in trials A cannabis-derived drug developed by Vertanical has shown efficacy in phase 3 for chronic back pain and could reach its first markets soon.
News EU clears first drug therapy for rare disease cALD Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
